Soligenix, Inc.’s common stock is listed on Nasdaq under the symbol SNGX. Stockholders and interested parties are urged to contact our main office in Princeton, New Jersey at 609-538-8200 or send an e-mail to firstname.lastname@example.org for further information.
- June 14, 2017: Corporate Presentation (pdf)
- April 25, 2017: RiVax® Correlates of Immune Protection: Serum Antibody Profiling Following Vaccination Reveals a Correlate of Immunity to Ricin Toxin (pdf)
- March 20, 2017: Watch the Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease presentation on YouTube
- December 16, 2016: Watch the Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis Webcast on YouTube
- August 2016: View the Dusquetide (SGX94) TechWatch Presentation on YouTube /
View the presentation PDF
Financial and Corporate Governance Information
- Soligenix Stock Quote (Website link)
- Soligenix Filings with the SEC (Website link)
- Code of Ethics
- Audit Committee Charter (PDF)
- Compensation Committee Charter (PDF)
- Nominating Committee Charter (PDF)
- Director Compensation and Stock Ownership Policy (PDF)
If you would like to receive our Investor Relations Packet, including reprints of scientific publications relating to our products, click here. Thank you for your interest.